Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Strosberg J, et al. Among authors: ruszniewski p. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32123969 Free PMC article. Clinical Trial.
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).
Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B; European Neuroendocrine Tumour Society. Plöckinger U, et al. Among authors: ruszniewski p. Neuroendocrinology. 2004;80(6):394-424. doi: 10.1159/000085237. Epub 2005 Apr 18. Neuroendocrinology. 2004. PMID: 15838182 Review. No abstract available.
Digestive endocrine tumors.
Cadiot G, Baudin E, Partensky C, Ruszniewski P. Cadiot G, et al. Among authors: ruszniewski p. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S91-2S97. Gastroenterol Clin Biol. 2006. PMID: 17151568 Free article. Review. No abstract available.
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Yao JC, et al. Among authors: ruszniewski p. J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933912 Free PMC article. Clinical Trial.
Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study.
Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d'Herbomez M, Guigay J, Mitry E, Cadiot G, Leboulleux S, Lombard-Bohas C, Borson-Chazot F, Ducreux M, Baudin E. Vezzosi D, et al. Among authors: ruszniewski p. Int J Biol Markers. 2011 Apr-Jun;26(2):94-101. doi: 10.5301/JBM.2011.8327. Int J Biol Markers. 2011. PMID: 21574156 Free article.
502 results